Form 4: Cadrenal Therapeutics CEO Sells 500 Shares

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 500 shares of common stock under a Rule 10b5-1 trading plan.

Summary

• Quang Pham, CEO and Chairman of Cadrenal Therapeutics, Inc. (CVKD), reported a sale of common stock.
• The transaction involved 500 shares of common stock.
• The shares were sold on October 2, 2025, at a weighted average price of $14.13 per share, with prices ranging from $14.04 to $14.27.
• The sale was executed pursuant to a Rule 10b5-1 trading arrangement.
• Following the transaction, Quang Pham directly beneficially owns 202,133 shares and indirectly owns 200,000 shares through The PVBQ Living Trust.

Sentiment

Score: 5

Explanation: The transaction is a small, pre-planned sale by an insider under a Rule 10b5-1 arrangement, which typically has a neutral impact on sentiment unless the volume is significant.

Negatives

• Quang Pham, CEO and Chairman, sold 500 shares of common stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Quang Pham is the Trustee of The PVBQ Living Trust, which holds 200,000 shares indirectly for which Mr. Pham's child is the sole beneficiary.

Stakeholder Impact

• Shareholders: A minor, pre-planned insider sale is unlikely to have a significant impact on shareholder sentiment or the company's valuation.

Key Dates

Recommendation

The filing reports a minor, pre-planned insider sale by the CEO under a Rule 10b5-1 arrangement. This transaction alone does not provide sufficient new information to warrant a change in investment thesis or a strong buy/sell recommendation. Investors should continue to hold and monitor the company's operational and financial performance.

Keywords

Cadrenal Therapeutics, CVKD, Quang Pham, Insider Trading, Form 4, Stock Sale, Rule 10b5-1